^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    INCB052793

    i
    Other names: INCB 52793, INCB052793, INCB52793, INCB 052793
    Associations

    News

    Trials
    Company:
    Incyte
    Drug class:
    JAK1 inhibitor
    Related drugs:
    Associations

    News

    Trials
    over4years
    Selective Inhibition of JAK1 Primes STAT5-Driven Human Leukemia Cells for ATRA-Induced Differentiation. (PubMed, Target Oncol)
    JAK1i+ ATRA lead to decreases in cell cycle followed by myeloid differentiation and cell death in human leukemias. These findings highlight potential uses of ATRA-based differentiation therapy of non-M3 human leukemia.
    Journal
    |
    JAK1 (Janus Kinase 1)
    |
    Jakafi (ruxolitinib) • INCB052793